海角社区

Dr. Daadi is an expert in regulated translational research and has developed therapeutic neural stem cell lines (NSC) for clinical use in Parkinson’s disease, stroke, and to target brain tumors in both industrial and academic settings. He discovered a novel technique of engineering these stem cell lines from pluripotent human embryonic stem cells and continues to develop this therapeutic cell line for clinical use. Dr. Daadi came to Texas Biomed in 2014 and is the team leader for the SNPRC Regenerative Medicine and Aging research unit. Results from his studies are the foundation of translational research and help to repair diseased or injured brain through transplantation of highly purified NSCs and stimulation of internal repair mechanisms.

Dr. John Volpi specializes in the evaluation of hospitalized patients and outpatients with cerebrovascular disease, such as ischemic and hemorrhagic stroke as well as the critical care of patients with other neurological diseases. His primary clinical and research interests are in the management and prevention of ischemic stroke and the critical care of patients with neurological illnesses, such as intracerebral hemorrhage, trauma, and nervous system infections.

Dr. Volpi麓s research interests are in the management and prevention of ischemic stroke, and the critical care of patients with neurological illnesses such as intracerebral hemorrhage, epilepsy, and nervous system infections. His studies also involve the use of ultrasound in the evaluation of blood flow to the brain and development of novel therapies for improving patient outcomes in stroke.

Bernadette Boden-Albala, MPH, DrPH, is the Founding Dean of the UC Irvine Joe C. Wen School of Population & Public Health. A renowned researcher and academic administrator with more than 30 years of experience, she holds several leadership roles within the field of public health, at the UC Irvine campus, and at the UC-system level. Boden-Albala has dedicated her career to promoting health equity for all, defining and intervening on social determinants of disease, and leading community-level health assessments and solutions. She has expertise in cardiovascular disease and stroke, emerging infectious diseases, epidemiology as well as global health.

, is a board-certified neurosurgeon who specializes in complex cranial surgery, endovascular neurosurgery, stroke care, and neurological oncology. He is chair of the Department of Neurological Surgery at UC San Diego Health and professor of neurological surgery, radiology and neurosciences and the Don and Karen Cohn Chancellor's Endowed Chair in Neurosurgery at UC San Diego School of Medicine.
Khalessi provides both open surgical and minimally invasive, catheter-based approaches to complex neurosurgical conditions, including brain tumors, aneurysms, arteriovenous malformations (AVM), carotid disease and ischemic stroke.
Khalessi is a founding member of the Medical Device Innovation Consortium (MDIC) that advises the FDA on early clinical feasibility for emerging neurovascular devices. He serves on the NIH Interventional Advisory Panel for StrokeNet, which provides scientific oversight for federally funded research in neurovascular disease.

Dr. Hegde earned his Ph.D. in Biochemistry and Neurosciences from the University of Mysore, India in 2006. He performed his graduate research at the Max-Planck Institute of Biophysical Chemistry, Gottingen, Germany as a DST-DAAD visiting fellow, and at the Indian Institute of Science (IISc), Bangalore, India. He held an Assistant Professor appointment at the University of Texas Medical Branch at Galveston, Texas, USA before becoming a member of the Houston Methodist Research Institute in 2013. As a member of the Research Institute cancer and neuroscience research programs, he directs a research program focusing on understanding the role of genome damage repair in cell death (neurodegenerative diseases) and cell proliferation (cancer) and its potential exploitation in therapeutics. Dr. Hegde has also been a member of grant review boards for the Alzheimer’s Association, USA, Netherlands Organization for Scientific Research, French Scientific Grants (FMRM) and the Motor Neuron Disease Association, UK, in addition to NIH and DOD-CDMRP study sections. He is a Deputy Chief Editor for the Springer Journal Metabolic Brain Disease and Associate Editor for the Journal of Alzheimer’s Disease and serves on the editorial boards of the American Journal of Neurodegenerative Diseases, Jacobs Journal of Radiation Oncology and Research, Journal Neuroscience Research and Therapeutics, the Chinese Journal of Biology, and a peer-reviewer for more than 30 international journals.
Dr. Hegde has published over 90 peer-reviewed publications including more than a dozen as senior author. He has also published five book chapters, edited a book on ALS and four journal special issue collections.  These articles have received nearly 3000 citations. He has received several awards including gold medals in Masters, New Investigator awards from the Alzheimer’s Association, the Environmental Mutagenesis Society, Researcher of the Month (May 2011) at UTMB and prestigious Gopal Krishna Memorial Young Scientist award from ASIOA. He has recently been awarded the Career Cornerstone award from Houston Methodist for outstanding translational research contributions.



Description of Research

Dr. Hegde’s research program focuses on delineating the molecular mechanisms underlying neurodegenerative diseases with a primary emphasis on genome damage and their repair inhibitions/deficiencies in neurons. His laboratory is interested in Amyotrophic Lateral Sclerosis (ALS), Parkinson’s Disease (PD) and Stroke. He showed that DNA repair inhibitions/deficiencies play a key role in the etiology of neurodegenerative diseases. He demonstrated that transition metals, iron and copper, act as a ‘double whammy’ by both inducing DNA damage and by inhibiting their repair via direct binding and oxidation of NEIL enzymes involved in oxidized DNA base repair. These studies were funded by American Parkinson’s Disease Association. His current studies focus on characterizing the role of ALS-linked RNA binding protein TDP-43 in DNA double-strand break repair and testing the hypothesis that TDP-43’s nuclear clearance and aggregation in ALS (and other neurodegenerative diseases) cause deficient DNA double-strand repair and contributes significantly to cell death. In another project funded by Alzheimer’s Association’s New Investigator grant, he is delineating the mechanism of genotoxicity of amyloid proteins and exploring its prevention by natural compounds. In collaboration with Dr. Sankar Mitra, he is also exploring the potential of genome repair inhibitions in cancer therapeutics. Dr. Hegde’s research program is supported by NIH/NINDS R01, Muscular Dystrophy Association, ALS Association, Alzheimer’s Association and Melo Foundation.

 


Areas Of Expertise
Genome damage response, DNA repair, Neurodegenerative diseases, Alzheimer’s disease, Parkinson’s disease, Amyotrophic Lateral Sclerosis (ALS), Stroke


Education & Training

Postdoctoral Associate, Department of Biochemistry and Molecular Biology, University of Texas Medical Branch at Galveston
MS, Karnataka University
PhD, University of Mysore, Karnataka
BS, Karnataka University

Dr. Steve Stice is a University of Georgia, DW Brooks Distinguished Professor and Director of the Regenerative Bioscience Center, who holds a Georgia Research Alliance Eminent Scholar endowed chair, and is CSO of ArunA Biomedical Inc. He has over 30 years of research and development experience in biotechnology and is a co-founder of several biotech start-ups, including ArunA Biomedical; the first company to commercialize a product derived from human pluripotent stem cells, and cell development used to facilitate approval of Pfizer’s current cognitive enhancing pharmaceuticals.
Prior to joining UGA, Stice was the co-founder and served as both CSO and CEO of Advanced Cell Technology, the first USA Company to advance to human clinical trials using human pluripotent stem cells. Additionally, he co-founded startups; Prolinia and Cytogenesis which later merged with what is now, ViaCyte.
Outside of his academic professorship and business role, Stice co-directs The Regenerative Engineering and Medicine research center, or REM, a joint collaboration between Emory University, Georgia Institute of Technology and UGA, and is also a group leader of EBICS: Emergent Behaviors of Integrated Cellular Systems, a National Science Foundation Science and Technology Center founded by the Massachusetts Institute of Technology. As an invited member, he sits on the Scientific Advisory Board for the Food and Drug Administration (FDA), and is serving on the Governing Committee of the first institute funded by the U.S. Department of Commerce (DOC); National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), the eleventh institute in the Manufacturing USA government network.
Stice is a world-renown expert in the field of pluripotent stem cell biology. In 2001, he directed work on derivation of three human pluripotent stem cell lines which were approved for federal funding by the NIH and President Bush. One of several noteworthy achievements for Stice, was producing the first cloned rabbit in 1987 and the first cloned transgenic calves in 1998 (George and Charlie). In 1997 his group produced the first genetically modified embryonic stem cell derived pigs and cattle. Notably, the Stice lab was one of only five NIH sponsored sites for training NIH investigators on the propagation, differentiation and use of hESC over a six year period.
Currently, the Stice lab is developing novel therapies and new technologies for drug screening and neurodegenerative disease, which could change the lives of those suffering with Parkinson’s, Stroke injury, and Alzheimer’s. This research has led to publications in Science and Nature journals, national news coverage (CBS, NBC, ABC and CNN) and the first US patents on cloning animals and cattle stem cells which was featured in the Wall Street Journal. Most recently, Stice was elected to NAI Fellow status, the highest professional distinction accorded solely to academic inventors. Georgia Bio also honored Stice that same year with the 2017 Georgia Bio Industry Growth Award.

, is a board-certified vascular neurologist. His expertise includes caring for patients with stroke, cerebrovascular diseases, and those who require neurological critical care. Hemmen directs the Comprehensive Stroke Center at UC San Diego Health and was instrumental in establishing the center as the first certified Stroke Center of Excellence in San Diego County.
As a professor at the University of California School of Medicine Department of Neurosciences, Hemmen directs the Stroke Fellowship Program and provides leadership and education to medical students, residents and fellows.
Hemmen is the lead investigator for numerous clinical trials in cerebrovascular disease. He investigates the use of neuroprotection and reperfusion therapies after acute ischemic stroke, as well as stroke prevention, recovery and research in intracerebral hemorrhage. He also leads the cerebrovascular research and trial coordination center that conducts national and international collaborative trials and researches new cures in all areas of cerebrovascular medicine.